Loading stock data…
MDXG
$3.64+0.03 (+0.83%)
Pre-Market$3.73+0.09 (+2.47%)· Last close May 5
MiMedx Group, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MiMedx Group, Inc. in the Healthcare sector is trading at $3.64. The stock is currently near its 52-week low of $3.03, remaining 39.4% below its 200-day moving average. Technical signals show neutral RSI of 44 and bullish MACD crossover, explaining why MDXG maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 44) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.64
Potential Upside
97.7%
Whystock Fair Value$7.20
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PU...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$493.24M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
10.38
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.65
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
12.54%
Volume
Today's trading volume
1.90M
Recent News
How Reimbursement Shifts Are Rewriting The MiMedx Group (MDXG) Investment Narrative
MiMedx Group is back in focus after analysts trimmed fair value estimates, with one key model now pointing to a reduced price target range that includes a shift from US$8.20 to US$6.50 per share. That change sits alongside broader research that highlights both pressure from reimbursement questions and specific factors that some analysts still see as supportive for the chronic wound care business over time. Read on to see what is driving the evolving narrative and how you can track it as new...
MiMedx Group, Inc. (NASDAQ:MDXG) Analysts Are Cutting Their Estimates: Here's What You Need To Know
It's shaping up to be a tough period for MiMedx Group, Inc. ( NASDAQ:MDXG ), which a week ago released some...
MiMedx Group (MDXG) Launches CHORIOFIX Placental Allograft for Complex, Tunneling Wounds
MiMedx Group Inc. (NASDAQ:MDXG) is one of the best biotech penny stocks to buy in 2026. On March 23, MiMedx officially announced the commercial launch of CHORIOFIX, the latest addition to its portfolio of advanced placental allografts. This organically developed product is a lyophilized human placental allograft designed to serve as a protective barrier for […]
MiMedx Group Inc (MDXG) Q1 2026 Earnings Call Highlights: Navigating Growth and Challenges
Despite strong growth in its surgical segment and a robust cash position, MiMedx Group Inc (MDXG) faces significant hurdles in its wound care business due to Medicare policy changes.
MiMedx (MDXG) Reports Q1 Loss, Tops Revenue Estimates
MiMedx (MDXG) delivered earnings and revenue surprises of +28.57% and +3.49%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?